1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cell MedX Corp.

Cell MedX Corp.

CMXC
Cell MedX Corp.US flagOther OTC
0.43
USD
- -
- -
126.33MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
0.02
0.02
- -
- -
- -
0.03
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.01
-0.5
-1.04
-0.51
-0.55
-0.31
-0.31
-0.23
-0.17
-0.12
-0.01
-0.01
Free Cash Flow per Basic Share
-0.01
-0.01
- -
-0.17
-0.31
-0.35
-0.16
-0.1
-0.26
-0.14
-0.11
-0.06
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
-0.02
-0.03
-0.52
-1.56
-1.82
-2.13
-2.34
-2.24
-2.27
-2.29
-2.41
-0.93
-0.58
Tangible Book Value per Share
0.01
- -
-0.01
-0.33
-0.68
-0.48
-0.38
-0.6
-0.43
-0.4
-0.48
-0.57
-0.08
-0.05
Basic Weighted Avg Shares
2
2
2
2
2
2
3
3
4
4
4
4
11
18
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-2,198.41
-5,756.09
-19,619.87
- -
- -
-1,083.6
-10,094.45
-11,074.91
-16,207.75
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
-2
-1
-2
-1
-1
-1
-1
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-2,421.56
-5,851.51
-20,087.56
- -
- -
-1,140.32
-13,469.92
-11,498.42
-17,923.32
- -
- -
Working Capital
- -
- -
- -
-1
-2
-1
-1
-2
-2
-2
-2
-2
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
-1
-1
-1
-2
-2
-2
-2
-2
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.2
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
May'24
Aug'25
Nov'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
5
4
8

Working Capital

FRC

•

in mil. unless spec.
May'24
Aug'25
Nov'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
337.06%
-5.94%
-65.35%
Free Cash Flow
352.07%
10.94%
-46.4%
Net Income, GAAP
539.95%
-23.94%
-71.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.04
-0.03
-0.03
- -
-0.12
2024
-0.02
-0.01
0.01
- -
-0.01
2025
- -
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David M. Jeffs
Sector
Healthcare
Industry
Medical - Devices
Address
123 West Nye Ln Carson City NV United States of America 89706
IPO Date
Aug 29, 2013
CIK
0001493712
Website
cellmedx.com
Similar Companies
Ambu A/S (AMBFF)
Cochlear Limited (COH.AX)
Hemcheck Sweden AB (publ) (HEMC.ST)
Contec Medical Systems Co.,Ltd (300869.SZ)
SofWave Medical Ltd. (SOFW.TA)
Avisa Diagnostics Inc. (AVBT.CN)
Business
StimCell Energetics Inc., formerly known as Cell MedX Corp., is a biotechnology enterprise dedicated to pioneering cellular energy solutions for advancing overall wellness and addressing significant health concerns. The company concentrates on the discovery, development, and commercialization of both therapeutic and non-therapeutic products designed to enhance cellular function. Its flagship offerings include the eBalance® Pro System, intended for clinical use by healthcare professionals, and the eBalance® Home System, which provides general wellness and pain management benefits for personal use. These systems are regulated by the eBalance® Console, which orchestrates pre-programmed microcurrent algorithms for wellness, pain management, and dual applications, targeting conditions such as diabetes, high blood pressure, neuropathy, and kidney function, as well as providing relief for various bodily pains. The company, which was originally incorporated in 2010 and is headquartered in Carson City, Nevada, officially rebranded to StimCell Energetics Inc. and completed a 1:15 reverse stock split in November 2024, with its shares trading under a temporary symbol before seeking a new one.

Company News

APIChat

  • accesswire.com

    StimCell Energetics Inc. (Formerly "Cell MedX Corp.") Announces Major Corporate Updates and Rebranding

  • newsfilecorp.com

    Cell MedX Corp. Closes Private Placement Financing

  • newsfilecorp.com

    Cell MedX Corp. Announces Resignation of Director

  • newsfilecorp.com

    Cell MedX Corp. Appoints Dr. George Adams as Chairman of the Board

  • newsfilecorp.com

    Cell MedX Corp. Announces New CEO and Directors and Debt Settlement

  • newsfilecorp.com

    Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order

  • newsfilecorp.com

    Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer